284.32
0.69%
-1.98
AMGEN Inc. stock is currently priced at $284.32, with a 24-hour trading volume of 2.28M.
It has seen a -0.69% decreased in the last 24 hours and a +2.47% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $285.2 pivot point. If it approaches the $283.6 support level, significant changes may occur.
AMGEN Inc. Stock (AMGN) Financials Data
AMGEN Inc. (AMGN) Revenue 2023
AMGN reported a revenue (TTM) of $28.19 billion for the quarter ending December 31, 2023, a +7.09% rise year-over-year.
AMGEN Inc. (AMGN) Net Income 2023
AMGN net income (TTM) was $6.72 billion for the quarter ending December 31, 2023, a +2.52% increase year-over-year.
AMGEN Inc. (AMGN) Cash Flow 2023
AMGN recorded a free cash flow (TTM) of $7.36 billion for the quarter ending December 31, 2023, a -16.23% decrease year-over-year.
AMGEN Inc. (AMGN) Earnings per Share 2023
AMGN earnings per share (TTM) was $12.49 for the quarter ending December 31, 2023, a +3.14% growth year-over-year.
AMGEN Inc. Stock (AMGN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Graham Jonathan P | EVP, Gen. Counsel & Secy. |
Nov 08 '23 |
Sale |
272.81 |
10,000 |
2,728,136 |
28,078 |
AMGEN INC | 10% Owner |
Sep 19 '23 |
Buy |
17.00 |
1,764,705 |
29,999,985 |
35,368,653 |
Gordon Murdo | EVP, Global Commercial Ops |
Aug 10 '23 |
Sale |
262.43 |
9,558 |
2,508,306 |
44,308 |
AMGEN Inc. Stock (AMGN) Latest News
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research
Amgen's Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says
Benzinga
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks Investment Research
Should You Invest in the iShares Biotechnology ETF (IBB)?
Zacks Investment Research
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Wall Street Awaits Consumer Confidence Data
Zacks Investment Research
About AMGEN Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Cap:
|
Volume (24h):